NEWS HIGHLIGHTS
Published Studies Related to Pentetate Zinc
Comparison of 1.0 M Gadobutrol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions: Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial. [2009.01.22]
CONCLUSION:: This study documents evidence for the noninferiority of a single i.v. bolus injection of 1.0 M gadobutrol (0.1 mmol/kg body weight) to 0.5 M gadopentetate (0.1 mmol/kg body weight) in the diagnostic assessment of liver lesions with contrast-enhanced MRI. The known excellent safety profile of gadobutrol was confirmed in this clinical trial and is similar to that of gadopentetate.
Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. [2007.04]
OBJECT: The goal in this article was to compare 0.1 mmol/kg doses of gadobenate dimeglumine (Gd-BOPTA) and gadopentetate dimeglumine, also known as gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA), for enhanced magnetic resonance (MR) imaging of intraaxial brain tumors... CONCLUSIONS: Lesion visualization, delineation, definition, and contrast enhancement are significantly better after administration of 0.1 mmol/kg Gd-BOPTA, potentially allowing better surgical planning and follow up and improved disease management.
Clinical Trials Related to Pentetate Zinc
Monoclonal Antibody Therapy in Treating Patients With Leukemia [Completed]
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus
pentetic acid calcium in patients with leukemia.
Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma [Recruiting]
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver
cancer-killing substances to them without harming normal cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of radiolabeled
monoclonal antibody when given together with pentetic acid calcium and to see how well they
work in treating patients with recurrent Hodgkin's lymphoma or non-Hodgkin's lymphoma.
Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA [Active, not recruiting]
In vivo study of human cerebral spinal fluid (CSF) flow is important to establish CSF flow
patency in the planning of intrathecal cancer treatment. Only one radiopharmaceutical,
namely In-111 pentetate (DTPA) (DRAXIMAGE, Inc, Kirkland, Quebec, Canada) is approved by the
FDA for human CSF imaging. The supply of this radiopharmaceutical is limited and not always
available on short notice.
This is a pilot study using Gallium-67 citrate, another cyclotron product with a physical
half-life of 3. 3 days and emits gamma rays at 93, 184 and 300 Kev which can be readily imaged
for several days. Upon entering the circulation, Ga-67 binds to serum transferrin and then
translocates to lactoferrin which is abundant in leukocytes and serve to localize tumor,
infectious sources and inflammatory tissues. It may be potentially useful to evaluate spinal
fluid flow patency as an alternative to In 111 DTPA. Simultaneous acquisition of nuclear
images, of multiple window (photopeaks) allows evaluation of individual radionuclides by a
single imaging session, therefore simultaneous imaging of In-111 DTPA and Ga-67 citrate in
the same patients will allow comparison of these 2 radiopharmaceuticals during the earlier
phase to study the bulk flow and during later phases to evaluate their retention in patients
during LM occurrence, LM remission and LM relapse.
Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer [Active, not recruiting]
RATIONALE: Diagnostic procedures such as sentinel lymph node biopsy may improve the ability
to detect breast cancer and determine the extent of disease.
PURPOSE: Phase II trial to study the effectiveness of sentinel lymph node biopsy to assess
axillary lymph nodes in women who have stage I or stage II breast cancer.
Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer [Active, not recruiting]
RATIONALE: Diagnostic procedures to detect cancer cells in sentinel lymph nodes may help plan
effective cancer treatment.
PURPOSE: Diagnostic trial to study the effectiveness of lymph node mapping and sentinel lymph
node lymphadenectomy in patients who are undergoing surgery to remove early-stage cancer of
the mouth.
|
